Azenta, Inc. · NASDAQ:AZTA

Azenta — Jefferies Healthcare Conference 2023

31 slides from Azenta's conference presentation, Jun 8, 2023

  1. Slide 1: Jefferies Healthcare Conference

    Slide 1: Jefferies Healthcare Conference

    Azenta Life Sciences Jefferies Healthcare Conference June 8, 2023

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that co

  3. Slide 3: Agenda

    Slide 3: Agenda

    AGENDA High Value Portfolio of Market Leading Offerings in Cold Chain of Custody and Sample Management Azenta – An Established Life Sciences Company with a Strong Track Record Serving Attractive High Growth End Markets Creating Value – On the Path to Sustained Growth and Higher Profitability 3 © 202

  4. Slide 4: Differentiated End-to-End Sample Management Portfolio

    Slide 4: Differentiated End-to-End Sample Management Portfolio

    Differentiated End-to-End Sample Management Portfolio ~$660M revenue, well-positioned for growth and 1 margin expansion in robust end markets Strong value proposition with Global platform that can support additional 2 capabilities and customers unique portfolio of sample-based solutions Healthy bala

  5. Slide 5: Azenta – An Established Life Sciences Company with a Strong Track Record

    Slide 5: Azenta – An Established Life Sciences Company with a Strong Track Record

    Azenta – An Established Life Sciences Company with a Strong Track Record Market Leading Offerings: Growth Rate (YtY)1 Products Services FY’22 YTD Q2’23 • Automated ultracold bio-sample 45% 55% storage • Biorepository services 8% 15% • Genomics services reported reported • Cold chain solutions for em

  6. Slide 6: Established Early, Recognized as a Leader in Life Sciences

    Slide 6: Established Early, Recognized as a Leader in Life Sciences

    Established Early, Recognized as a Leader in Life Sciences To >$500M by FY’22 ~$660M • Genomic services and analytics • Additional sample repository and consumables & instruments (C&I) $555M capabilities • Sample sourcing • Informatics To $100M in First 5 Years • Automated ultracold stores • Consuma

  7. Slide 7: Agenda

    Slide 7: Agenda

    AGENDA High Value Portfolio of Market Leading Offerings in Cold Chain of Custody and Sample Management Azenta – An Established Life Sciences Company with a Strong Track Record Serving Attractive High Growth End Markets Creating Value – On the Path to Sustained Growth and Higher Profitability 7 © 202

  8. Slide 8: Strategically Positioned to Address Market Needs

    Slide 8: Strategically Positioned to Address Market Needs

    Strategically Positioned to Address Market Needs 2X >30% >2,000 Growth in outsourced 2021 FDA drug approvals Cell & Gene Therapy active samples in 5 years require temperature control trials today1 • Increased requirements for • Regulations necessitate • CGT market poised for better sample management

  9. Slide 9: An Impressive Roster of Customers Use Azenta’s Solutions

    Slide 9: An Impressive Roster of Customers Use Azenta’s Solutions

    An Impressive Roster of Customers Use Azenta’s Solutions 9,000+ 24,000 Top 5 33 Citations in Total customers served by Azenta Best-selling pharma 20 of 20 scientific journals products: clinical samples managed by SRS Nobel laureate Top pharma/biotech labs use Azenta served by Azenta Pharma / Biotech

  10. Slide 10: Building on a 15+ Year Global Large Pharma Relationship

    Slide 10: Building on a 15+ Year Global Large Pharma Relationship

    CUSTOMER CASE STUDY Building on a 15+ Year Global Large Pharma Relationship: Enabling a Best-in-Class R&D Program 2000s-2019 2020 2021 2022 2023 Early adopter of automated Expanded in Installed systems; Added Sample Genomics; 100M+ sample Reached >5M Repository preferred capacity samples stored GENE

  11. Slide 11: Azenta Portfolio – Diverse and Differentiated

    Slide 11: Azenta Portfolio – Diverse and Differentiated

    Azenta Portfolio – Diverse and Differentiated Next Generation Sequencing B Medical 16% Sanger Systems Sequencing 17% 9% Gene Synthesis Products & Other Services Ultracold 13% 45% Systems 55% & Services 13% Sample Consumables Repository & Instruments Solutions 15% 17% Note: FY’23 Year-to-Date (6 mont

  12. Slide 12: B Medical, a Global Leader in Temperature-Controlled Storage

    Slide 12: B Medical, a Global Leader in Temperature-Controlled Storage

    B Medical, a Global Leader in Temperature-Controlled Storage and Transportation Solutions ✓ Distinct and Attractive Business • A global leader in vaccine cold chain • Unique position to serve fast-growing emerging markets Business Today • Established critical link in the human health cold chain ✓ Tr

  13. Slide 13: Agenda

    Slide 13: Agenda

    AGENDA High Value Portfolio of Market Leading Offerings in Cold Chain of Custody and Sample Management Azenta – An Established Life Sciences Company with a Strong Track Record Serving Attractive High Growth End Markets Creating Value – On the Path to Sustained Growth and Higher Profitability 13 © 20

  14. Slide 14: Long Track Record of Growth Supported with Organic and M&A Investment

    Slide 14: Long Track Record of Growth Supported with Organic and M&A Investment

    Long Track Record of Growth Supported with Organic and M&A Investment Revenue $700 $ millions Acquisitions $600 33% CAGR COVID $500 Organic $400 $300 $200 $100 $- FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23E Note:FY23E based on the midpoint of FY’23 guidance as of May 9, 2023, and is being provided

  15. Slide 15: Business Realignment Enhances Commercial Strategy and Supports Growth

    Slide 15: Business Realignment Enhances Commercial Strategy and Supports Growth

    Business Realignment Enhances Commercial Strategy and Supports Growth Sample 1 Management Solutions Operating 2 Multiomics Units 3 B Medical Three operational groups aligned with industry end-users and purchase decision-makers Note: Effective 10/1/23, at the start of FY24 15 © 2023 Azenta, Inc. • Pr

  16. Slide 16: Margin Improvement Actions In Process

    Slide 16: Margin Improvement Actions In Process

    Margin Improvement Actions In Process Integration and Realignment of Internal Rationalization of Operations Acquired Businesses • $14M annual net cost savings • $15M annual cost savings by • Expected to drive 2 points of the end of CY2023 to support +4pts EBITDA margin enhancement in the second half

  17. Slide 17: Continued Disciplined Approach to Capital Deployment

    Slide 17: Continued Disciplined Approach to Capital Deployment

    Continued Disciplined Approach to Capital Deployment Operational CapEx ~6-9% of Revenue Research & ~4-6% of Revenue Development Shareholder Returning Capital Through $1B Value Share Repurchases by CY23 End Strong Balance ~$900M Additional Cash Available Sheet for Deployment* *Estimated based on $1.5

  18. Slide 18: Guidance As Provided May 9, 2023

    Slide 18: Guidance As Provided May 9, 2023

    Guidance As Provided May 9, 2023 Continuing Operations May Q2’22 Q3’22 Q4’22 Q1’23 Q2’23 Guidance Q3’23 ** Total Revenue ($M) $146 $133 $138 $178 $148 $150 - $168 Organic Growth %* 12% 6% 2% (1%) (8%) ~2% Adjusted EBITDA ($M)* $19 $14 $9 $12 ($2) ($3) - $6 EPS* $0.12 $0.12 $0.16 $0.12 ($0.06) ($0.07

  19. Slide 19: Differentiated End-to-End Sample Management Portfolio

    Slide 19: Differentiated End-to-End Sample Management Portfolio

    Differentiated End-to-End Sample Management Portfolio ~$660M revenue, well-positioned for growth and 1 margin expansion in robust end markets Strong value proposition with Global platform that can support additional 2 capabilities and customers unique portfolio of sample-based solutions Healthy bala

  20. Slide 20: Appendix

    Slide 20: Appendix

    / \ AZENTA LIFE SCIENCES Appendix

  21. Slide 21: 10+ Years Building a Leading-Edge Life Sciences Company

    Slide 21: 10+ Years Building a Leading-Edge Life Sciences Company

    10+ Years Building a Leading-Edge Life Sciences Company 2011-2012 2013-2014 2015-2016 2017-2018 2019-2020 2021 2022-2023 •BioCision 2 •GENEWIZ •Abeyance •Barkey •RTS •Matrical •FluidX •PBMMI •RURO •B Medical •Nexus •BioCision 1 •BioStorage •FreezerPro •Trans-Hit Azenta Life •Ziath Technologies •4tit

  22. Slide 22: Portfolio Offering Examples

    Slide 22: Portfolio Offering Examples

    Portfolio Offering Examples Automated Stores Sample Repository Solutions B Medical Systems SampleStoreTM BioStoreTM BioStoreTM III Cryo Consumables & Instruments Genomic Services Sanger Gene Next Sequencing Synthesis Generation Sequencing 22 © 2023 Azenta, Inc. • Proprietary Information

  23. Slide 23: GAAP to Non-GAAP Reconciliation

    Slide 23: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation Continuing Operations – Total Azenta $ millions, except EPS Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Revenue 139.7 145.5 132.7 137.6 178.4 148.4 GAAP gross profit 67.0 70.8 59.6 58.1 73.9 53.2 Gross profit margin 48.0% 48.7% 44.9% 42.3% 41.4% 35.9% Amortization

  24. Slide 24: GAAP to Non-GAAP Reconciliation – Segments

    Slide 24: GAAP to Non-GAAP Reconciliation – Segments

    GAAP to Non-GAAP Reconciliation Continuing Operations – Segments $ millions, except EPS Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Life Sciences Products Revenue 49.9 53.6 47.4 48.4 89.7 58.9 GAAP gross profit 22.7 26.3 21.0 19.1 33.0 14.3 Gross profit margin 45.5% 49.0% 44.4% 39.4% 36.8% 24.3%

  25. Slide 25: Revenue and Gross Margin Quarterly Trend

    Slide 25: Revenue and Gross Margin Quarterly Trend

    Revenue and Gross Margin Quarterly Trend Continuing Operations Non GAAP Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Genomics Revenue 63.9 65.0 59.4 62.7 61.1 62.2 Genomics Gross Margin 32.6 32.1 27.3 28.2 28.9 28.2 Genomics Gross Margin % 51.0% 49.4% 46.0% 45.0% 47.4% 45.4% SRS Revenue 25.9 26.9

  26. Slide 26: GAAP to Non-GAAP Reconciliation – Genomics and SRS

    Slide 26: GAAP to Non-GAAP Reconciliation – Genomics and SRS

    GAAP to Non-GAAP Reconciliation Continuing Operations – Genomics and SRS $ millions Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Life Sciences Services- Genomics Revenue 63.9 65.0 59.4 62.7 61.1 62.2 GAAP gross profit 31.1 31.1 25.9 26.5 27.7 27.0 Gross profit margin 48.7% 47.9% 43.6% 42.3% 45.4%

  27. Slide 27: GAAP to Non-GAAP Reconciliation – B Medical and Products

    Slide 27: GAAP to Non-GAAP Reconciliation – B Medical and Products

    GAAP to Non-GAAP Reconciliation Continuing Operations – B Medical and Products ex B Medical $ millions, except EPS Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 B Medical Revenue - - - - 41.8 15.1 GAAP gross profit - - - - 14.1 (1.3) Gross profit margin - - - - 33.7% (8.7%) Amortization expense -

  28. Slide 28: Net Income to Adjusted EBITDA Reconciliation

    Slide 28: Net Income to Adjusted EBITDA Reconciliation

    Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Net income 43.3 2,119.9 (9.6) (20.8) (11.2) (4.9) Income (Loss) from discontinued operations, net of tax (40.5) (2,121.7) 2.6 15.5 - 2.9 Net income (Loss) from continuing ope

  29. Slide 29: Operating Profit to Adjusted EBITDA Reconciliation

    Slide 29: Operating Profit to Adjusted EBITDA Reconciliation

    Operating Profit to Adjusted EBITDA Reconciliation Continuing Operations – Segments Life Science Products Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Operating Profit (Loss) 4.2 5.0 2.0 (0.1) (3.8) (16.4) Adjustments: Depreciation 0.7 0.9 0.9 1.2 3.1 3.3 Amortization of intangible assets 0.2 0.3

  30. Slide 30: Operating Profit to Adjusted EBITDA Reconciliation

    Slide 30: Operating Profit to Adjusted EBITDA Reconciliation

    Operating Profit to Adjusted EBITDA Reconciliation Continuing Operations – B Medical and Products ex B Medical B Medical Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Operating Profit (Loss) - - - - (0.5) (9.0) Adjustments: Depreciation - - - - 2.1 2.0 Amortization of intangible assets - - - - 3.9

  31. Slide 31: Calculation of Organic Revenue Excluding COVID

    Slide 31: Calculation of Organic Revenue Excluding COVID

    Calculation of Organic Revenue Excluding COVID Continuing Operations Growth Metrics $ millions Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Revenue 18% 12% 3% 0% 28% 2% Acquisitions/divestitures (2%) (1%) 0% (3%) (33%) (13%) Currency exchange rates (0%) 1% 3% 4% 4% 3% Organic revenue 16% 12% 6% 2

Source: company website

More decks from Azenta, Inc.

All 52 Azenta decks